| Literature DB >> 20835386 |
Irma Podolak1, Agnieszka Galanty, Danuta Sobolewska.
Abstract
Saponins are natural glycosides which possess a wide range of pharmacological properties including cytotoxic activity. In this review, the recent studies (2005-2009) concerning the cytotoxic activity of saponins have been summarized. The correlations between the structure and the cytotoxicity of both steroid and triterpenoid saponins have been described as well as the most common mechanisms of action.Entities:
Year: 2010 PMID: 20835386 PMCID: PMC2928447 DOI: 10.1007/s11101-010-9183-z
Source DB: PubMed Journal: Phytochem Rev ISSN: 1568-7767 Impact factor: 5.374
Cytotoxic triterpene saponins (2005–2009)
| Source | Saponoside | Cell line | Concentration | Assay/effect | References |
|---|---|---|---|---|---|
|
| 5 saponins (21, 22, 26, 27, and 28) | 59 cell lines from nine different human cancers including leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast |
| SRB; cytotoxic | Zhang and Li ( |
| (Hippocastanceae) | Compounds 26–28 | ||||
| 0.175–8.71 | |||||
|
| Albizosides A-C, most potent: |
| MTT; cytotoxic | Liu et al. ( | |
| (Osb.) Merr., (Fabaceae/Mimosoidae) | Albizoside C | HCT-8 | 0.4 | ||
| Bel-7402 | 0.4 | ||||
| BGC-823 | 1.7 | ||||
| A549 | 0.01 | ||||
| A2780 | 0.3 | ||||
| Control: camptothecin | |||||
| HCT-8 | 3.2 | ||||
| Bel-7402 | 12.5 | ||||
| BGC-823 | 9.7 | ||||
| A549 | 3.1 | ||||
| A2780 | 0.3 | ||||
|
|
| MTT; cytotoxic | Noté et al. ( | ||
| Coriarioside A | HCT 116 | 4.2 | |||
| HT-29 | 2.7 | ||||
| Gummiferaoside C | HCT 116 | 6.7 | |||
| HT-29 | 7.9 | ||||
| Control: paclitaxel | |||||
| HCT 116 | 3.5 × 10−3 | ||||
| HT-29 | 3.4 × 10−3 | ||||
|
|
| CellTiter Glo luminescent; antiproliferative | Cao et al. ( | ||
| (J. F. Gmel.) C. A. Sm. var. | Gummiferaoside A | A2780 | 0.37 | ||
| MDA-MB-435 | 0.84 | ||||
| HT-29 | 6.61 | ||||
| H522-T1 | >10 | ||||
| U937 | 0.19 | ||||
| Gummiferaoside B | A2780 | 0.70 | |||
| MDA-MB-435 | ND | ||||
| HT-29 | ND | ||||
| H522-T1 | ND | ||||
| U937 | ND | ||||
| Gummiferaoside C | A2780 | 0.26 | |||
| MDA-MB-435 | 0.48 | ||||
| HT-29 | 0.61 | ||||
| H522-T1 | 0.64 | ||||
| U937 | 0.29 | ||||
| Control: actinomycin D, vinblastine—data not given | |||||
|
| Julibroside J21 | Bel-7402 | 10 μg ml−1 (80.8% inhib.) | SRB; cytotoxic | Zou et al. ( |
|
| 3- | HEPG2 |
| SRB; cytotoxic | Melek et al. ( |
| 3- | 10.0 | ||||
|
| 11 ardisianosides A-K together with 10 known saponins; most potent: |
| MTT; cytotoxic | Chang et al. ( | |
| HL-60 | 1.9 | ||||
| 3β- | KATO-III | 0.4 | |||
| A549 | 3.7 | ||||
| Control: etoposide | |||||
| HL-60 | 0.3 | ||||
| KATO-III | 0.1 | ||||
| A549 | 20.9 | ||||
|
| 5 saponins, most potent: |
| MTT; cytotoxic | Tian et al. ( | |
| 3β- | U251MG | 2.57 | |||
| Human astrocytes | >100 | ||||
| Control: nimustine hydrochloride | |||||
| U251MG | 0.98 | ||||
| Human astrocytes | >100 | ||||
|
| 15 saponins, most potent: | Brine shrimp |
| Brine shrimp lethality assay | Sivaramakrishna et al. ( |
| (Linn.) Pennel (Scrophulariaceae) | Bacopasaponin C | 3.9 | |||
| Control: podophyllotoxin | |||||
| 4.5 | |||||
|
| Caryocaroside II-7 | Human keratinocytes |
23.0 | XTT; cytotoxic | Magid et al. ( |
|
| Caryocaroside II-22 | 20.9 | |||
|
| 11 saponins, most potent: |
| MTT; cytotoxic | Tabatadze et al. ( | |
| Giganteoside D | MEL-5 | 7.50 | |||
| HL-60 | 3.15 | ||||
| Giganteoside E | MEL-5 | 7.50 | |||
| HL-60 | 6.80 | ||||
| Control: camptothecin | |||||
| MEL-5 | 0.40 | ||||
| HL-60 | 0.05 | ||||
|
| Series of triterpene glycosides, most potent: |
| MTT; coulter counter; antiproliferative | Einbond et al. ( | |
| 25-acetyl-7,8-didehydrocimigeno 3- | MDAMB-453 | 3.2 | |||
|
| 3 saponins, most potent: | HL-60 | 2 μmol l−1 | NRR; cytotoxic | Jin et al. ( |
| (Cucumariidae) | Frondoside A | ||||
|
| 9 compounds, most potent: |
| MTT; cytotoxic | Ma et al. ( | |
| dianversicoside C | HFL-I | 3.2 | |||
| EVC-304 | 3.6 | ||||
| BGC-803 | 3.1 | ||||
| MCF-7 | >10 | ||||
| Hep G2 | >10 | ||||
| Control: cisplatin | |||||
| HFL-I | 0.11 | ||||
| EVC-304 | 0.49 | ||||
| BGC-803 | 6.8 | ||||
| MCF-7 | 3.9 | ||||
| Hep G2 | 7.7 | ||||
|
|
| SRB; cytotoxic | Ahmed et al. ( | ||
| Durantanin IV | HepG2 | 1.68 | |||
| Durantanin V | 1.07 | ||||
|
|
| MTT; cytotoxic | Khanna and Kannabiran ( | ||
| Dasyscyphin C | HeLa | 50.0 | |||
| Control: 5-fluorouracil | |||||
| 36 | |||||
|
| Lotoidosides A-G, most potent: |
| MTT; antiproliferative | Hamed et al. ( | |
| Lotoidoside E | J774.A1 | 0.018 | |||
| HEK-293 | 0.02 | ||||
| WEHI-164 | 0.03 | ||||
| Control: 6-mercaptopurine | |||||
| J774.A1 | 0.003 | ||||
| HEK-293 | 0.007 | ||||
| WEHI-164 | 0.017 | ||||
|
|
| MTT; antiproliferative | Kiem et al. ( | ||
| Glochierioside A | HL-60 | 5.5 | |||
| HT-29 | 6.8 | ||||
| MCF-7 | 29.1 | ||||
| SK-OV-3 | 22.7 | ||||
| Glochierioside B | HL-60 | 6.6 | |||
| HT-29 | 18.6 | ||||
| MCF-7 | 36.1 | ||||
| SK-OV-3 | 16.0 | ||||
| Control: mitoxantrone | |||||
| HL-60 | 7.2 | ||||
| HT-29 | 8.4 | ||||
| MCF-7 | 10.3 | ||||
| SK-OV-3 | 12.1 | ||||
|
| Gordonosides, most potent: |
| MTT; cytotoxic | Yu et al. ( | |
| Gordonoside C | HCT-8 | 1.2 | |||
| Bel-7402 | 0.7 | ||||
| BGC-823 | 2.5 | ||||
| A549 | 1.8 | ||||
| A2780 | 0.4 | ||||
| Control: paclitaxel | |||||
| HCT-8 | 3.6 | ||||
| Bel-7402 | 6.3 | ||||
| BGC-823 | 0.04 | ||||
| A549 | 1.0 × 10−3 | ||||
| A2780 | 0.9 | ||||
|
| Gymnemagenol | HeLa |
37.0 | MTT; cytotoxic | Khanna and Kannabiran ( |
Control: 5-fluorouracil 36.0 | |||||
|
| Several saponins, most potent: |
| MTT; cytotoxic | Huang et al. ( | |
| Hydrocosisaponin E | KB | 8.54 | |||
| Daoy | 5.21 | ||||
| WiDr | 5.06 | ||||
| KB | 14.03 | ||||
| Daoy | 4.89 | ||||
| WiDr | 4.24 | ||||
| Control: mitomycin-C | |||||
| Hydrocotyloside VII | KB | 0.04 | |||
| Daoy | 0.07 | ||||
| WiDr | 0.05 | ||||
|
| 19 saponins, most potent: |
| MTT; cytotoxic | Li et al. | |
| Impatienoside G | HL-60 | 21.8 | |||
| KATO-III | 36.7 | ||||
| A549 | 24.8 | ||||
| Control: etoposide | |||||
| HL-60 | 0.3 | ||||
| KATO-III | 0.1 | ||||
| A549 | 20.6 | ||||
|
| Macranthoside B |
| MTT; antiproliferative | Wang et al. ( | |
| (Caprifoliaceae) | HepG2 | 10.1 | |||
| MGC-803, | 16.8 | ||||
| MCF-7 | 12.61 | ||||
| SW1116 | 14.55 | ||||
| U251 | 18.26 | ||||
| C6 | 14.35 | ||||
| B16F1 | 15.30 | ||||
| B16F10 | 16.74 | ||||
|
| Capilliposide D | A2780 |
0.2 μg ml−1 | No data; cytotoxic | Tian et al. ( |
|
| 25 μg ml−1 | Trypan blue exclusion; cytotoxic | Galanty et al. ( | ||
| LTS-4 | HTB-140 HSF | (50.1% dead cells) (68.3% dead cells) | |||
|
| Ginsenoside Rk1 | HepG2 | 75 μmol l−1 (55% dead cells) | Cell counting kit-8 (tetrazolium salt); cytotoxic | Kim et al. ( |
|
| 10 saponins, most potent: |
| MTT; cytotoxic | Qiu et al. ( | |
| Ginsenoside Rk1 | MCF-7 | 20.0 | |||
|
|
| Brine shrimp lethality assay; cytotoxic | Inoue et al. ( | ||
| Physenoside S7 | Brine shrimp | 8.5 | |||
| Physenoside S8 | 22.1 | ||||
| Control: etoposide phosphate | |||||
| 3.5 | |||||
|
| 4 saponins, most potent: buddlejasaponin IV |
| SRB; cytotoxic | Tundis et al. ( | |
| (Apiaceae) | ACHN | 7.9 | |||
| A375 | 14.6 | ||||
| C32 | 26.9 | ||||
| MCF-7 | >50 | ||||
| LNCaP | >50 | ||||
| A549 | 38.3 | ||||
| Huh-7D12 | >50 | ||||
| COR-L23 | 0.4 | ||||
| CaCo-2 | 40.7 | ||||
| 142BR | >50 | ||||
| Control for MCF-7: Taxol® | |||||
| 0.09 | |||||
|
|
| SRB; cytotoxic | Zhang et al. ( | ||
| 3- | MKN-45 | 0.442 | |||
| HCT-116 | 0.052 | ||||
| Intercedenside B | MKN-45 | 0.378 | |||
| HCT-116 | 0.066 | ||||
| Control: 10-hydroxy-camptothecin | |||||
| MKN-45 | 0.164 | ||||
| HCT-116 | 0.135 | ||||
|
| 17 saponosides; most potent: oleanolic acid 3- |
| SRB; antiproliferative | Bang et al. ( | |
| A-549 | 2.56 | ||||
| SK-OV-3, | 2.31 | ||||
| SK-MEL-2 | 1.57 | ||||
| HCT15 | 8.36 | ||||
| Control: doxorubicin | |||||
| A-549 | 0.017 | ||||
| SK-OV-3, | 0.094 | ||||
| SK-MEL-2 | 0.036 | ||||
| HCT15 | 0.792 | ||||
|
| 13 saponins most potent: sapinmusaponin K |
| MTT; cytotoxic | Huang et al. ( | |
| Hela | 18.10 | ||||
| WiDr | 19.31 | ||||
| KB | 5.49 | ||||
| Daoy | 7.09 | ||||
| Hepa59T/VGH | 11.07 | ||||
| Control: mitomycin-C | |||||
| Hela | 0.52 | ||||
| WiDr | 0.38 | ||||
| KB | 0.70 | ||||
| Daoy | 0.38 | ||||
| Hepa59T/VGH | 0.35 | ||||
|
| 5 saponins, most potent: |
| MTT; cytotoxic | Tapondjou et al. ( | |
| (Araliaceae) | Fatsiaside C1 | HCT 116 | <4 | ||
| Guaianin N | HT-29 | <4 | |||
| Control: paclitaxel | |||||
| HCT 116 | 9.9 × 10−3 | ||||
| HT-29 | 14.4 × 10−3 | ||||
|
|
| MTT; cytotoxic | Sánchez-Medina et al. ( | ||
| A 5:4 mixture comprising 3- | RAW 264.7 | 11.9 | |||
| and | Control: podophyllotoxin | ||||
| 3- | 29.0 nmol l−1 | ||||
|
| (urs-12-ene-3β,6β,6β-triol-3- | MDA-MB-231 | 25 μg ml−1 (80% inhib.) | PI; antiproliferative | Calabria et al. ( |
|
| Synaptoside A | HeLa |
8.6 | MTS; cytotoxic | Avilov et al. ( |
|
| 16 compounds; most potent: 1- |
| Calcein AM Fluorescent viability; cytotoxic | Cmoch et al. ( | |
| CEM | 10.4 | ||||
| MCF 7 | 22.7 | ||||
| A-549 | 43.3 | ||||
| HeLa | 34.7 | ||||
| BJ-H-tert | 38.7 | ||||
| RPMI 8226 | 19.4 | ||||
| G 361 | 22.7 | ||||
| Control: betulinic acid | |||||
| CEM | 40 | ||||
| MCF 7 | >50 | ||||
| A-549 | >50 | ||||
| HeLa | 47.6 | ||||
| BJ-H-tert | >50 | ||||
| RPMI 8226 | 34.6 | ||||
| G 361 | >50 | ||||
|
| 6 saponins: most potent xanifolia-Y3 |
| MTT; antiproliferative | Chan et al. ( | |
| OVCAR3 | 4.0 | ||||
| Control: paclitaxel | |||||
| 1.0 10−3 × 10−3 |
Cancer cell lines: Prostate: LNCaP, PC-3, DU-145; Leukemia: CEM, K562, HL60, *L1210, P388; Ovarian: SK-OV-3, A2780, OVCAR3, HO-8910; Breast: MDA-MB-231, MCF-7, MDA-MB-453, MDA-MB-435; Lung: A-549, H522-T1, COR-L23, NCI-H460, LTEP-a-2, *LA795, SPC-A-1; Melanoma: G361, MEL-5, A375, C32, *B16F1, *B16F10, SK-MEL-2, HTB-140; Colon: HCT-15, HT-29, WiDr, HCT116, CaCo-2, SW1116, HCT-8, DLD-1, LoVo, KM20L2; Lymphoma: U937; Pharynx: CNE, KB, Eca-109; Liver: HepG2, Huh-7D12, Bel-7402, Hepa59T/VGH, SMMC7721; Stomach: MGC-803, MKN-45, BGC-803, BGC823, KATO-III, SGC7901, AGS; Pancreas: Bx-PC3; CNS: U251, SF268, *C6, U251MG, U373, Daoy, XF498; Renal: ACHN; Bone: 1547, *WEHI-164, *XC, RPMI 8226; Uterus: HeLa
Normal cell lines: Fibroblasts: HSF, BJ-H-tert, 142BR, HFL-I, WS1; Macrophages: *RAW 264.7, *J774.A1; Epithelium/endothelium: EVC-304, MCF-10A; Kidney embryonic: HEK-293. * Murine origin
Concentration: IC50 half maximal inhibitory concentration; ED50 effective dose; GI50 growth inhibition; LC50 lethal concentration; LD50 lethal dose
Assays: MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; XTT—2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide; MTS—3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; WST-1—2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium
SRB—sulphorhodamine
PI—propidium iodide
NRR—neutral red release
Cytotoxic steroid saponins (2005–2009)
| Source | Saponoside | Cell line | Concentration | Assay | References |
|---|---|---|---|---|---|
|
|
| MTT; atiproliferative | Yokosuka and Mimaki | ||
| (25 | HL-60 | 12.3 | |||
| (25 | 9.4 | ||||
| (25 | 5.5 | ||||
| (25 | 11.3 | ||||
| Control: etoposide | |||||
| 0.20 | |||||
| (25 | 4.90 | Yokosuka et al. ( | |||
|
|
| Resazurin reduction; antiproliferative | Mskhiladze et al. ( | ||
| Yayoisaponin | A549 | 3.7 | |||
| DLD-1 | 5.6 | ||||
| WS1 | 3.0 | ||||
| Eruboside B | A549 | 5.3 | |||
| DLD-1 | 8.2 | ||||
| WS1 | 3.6 | ||||
| Aginoside | A549 | 5.8 | |||
| DLD-1 | 7.9 | ||||
| WS1 | 3.6 | ||||
| (25 | A549 | 9.0 | |||
| DLD-1 | 13.0 | ||||
| WS1 | 3.1 | ||||
| Leucospiroside A | A549 | 5.0 | |||
| DLD-1 | 7.2 | ||||
| WS1 | 4.55 | ||||
| (25 | A549 | 22.0 | |||
| DLD-1 | 22.0 | ||||
| WS1 | 14.5 | ||||
| (25 | A549 | 7.8 | |||
| DLD-1 | 8.9 | ||||
| WS1 | 7.7 | ||||
| Control: etoposide | |||||
| A549 | 1.1 | ||||
| DLD-1 | 4.8 | ||||
| WS1 | Not determined | ||||
| Control: 5-fluorouracil | |||||
| A549 | 48.0 | ||||
| DLD-1 | 11.0 | ||||
| WS1 | 20.01 | ||||
|
|
| MTT; cytotoxic | Chen et al. ( | ||
| 26- | SF-268 | 35.2 | |||
| 26- | NCI-H460 | 25.7 | |||
| SF-268 | 35.4 | ||||
|
| A mixture of: | 2 μg ml−1 | Trypan Blue | Sobolewska et al. ( | |
| (25 | B16 | (100% dead cells) | Exclusion; | ||
| and | XC | (100% dead cells) | cytotoxic | ||
| (25 | |||||
|
|
| MTT; cytotoxic | Bao et al. ( | ||
| Sarsapogenin | HepG2 | 42.4 (48 h) | |||
| 25.0 (72 h) | |||||
|
|
| SRB; cytotoxic | Zhou et al. ( | ||
| Filiasparoside A | A549 | 13.3 | |||
| MCF-7 | 11.2 | ||||
| Filiasparoside B | A549 | 16.4 | |||
| MCF-7 | 16.8 | ||||
| Filiasparoside C | A549 | 2.3 | |||
| MCF-7 | 3.0 | ||||
| Filiasparoside D | A549 | 2.4 | |||
| MCF-7 | 10.3 | ||||
| Aspafilioside A | A549 | 9.4 | |||
| MCF-7 | >20 | ||||
| Aspafilioside B | A549 | 7.6 | |||
| MCF-7 | 10.4 | ||||
| A549 | Control: etoposide | ||||
| 0.8 | |||||
| MCF-7 | 2.8 | ||||
|
| Asparanin A | HepG2 |
| MTT; cytotoxic | Liu et al. ( |
| 6.20 (24 h) | |||||
| 4.11 (48 h) | |||||
| 2.90 (72 h) | |||||
|
|
| MTT; cytotoxic |
| ||
| (25 | A2780 | 10.57 | |||
| MGC-803 | 8.39 | ||||
| CNE | 5.50 | ||||
| Asparagoside A | A2780 | 10.22 | |||
| HO-8910 | 5.04 | ||||
| (25 | HO-8910 | 24.83 | |||
| L1210 | 12.33 | ||||
| Sarsasapogenin | A2780 | 6.09 | |||
| (25 | A2780 | 18.85 | |||
| Eca-109 | 2.91 | ||||
| (25 | LTEP-a-2 | 2.85 | |||
| KB | 2.66 | ||||
| L1210 | 1.46 | ||||
| (25 | Eca-109 | 4.03 | |||
| MGC-803 | 3.72 | ||||
| LTEP-a-2 | 3.16 | ||||
| KB | 1.38 | ||||
| L1210 | 4.32 | ||||
| (25 | Eca-109 | 10.15 | |||
| CNE | 12.88 | ||||
| Control: doxorubicin | |||||
| A2780 | 0.15 | ||||
| HO-8910 | 1.45 | ||||
| Eca-109 | 0.36 | ||||
| MGC-803 | 0.72 | ||||
| CNE | 0.58 | ||||
| LTEP-a-2 | 1.33 | ||||
| KB | 0.43 | ||||
| L1210 | 0.26 | ||||
|
|
| SRB; cytotoxic | Kim et al. ( | ||
| Asparanin A | A549 | 2.05 | |||
| SK-OV-3 | 2.43 | ||||
| SK-MEL-2 | 2.41 | ||||
| XF498 | 2.56 | ||||
| HCT15 | 2.47 | ||||
| Aspaoligonin A | A549 | 2.25 | |||
| SK-OV-3 | 2.66 | ||||
| SK-MEL-2 | 2.53 | ||||
| XF498 | 2.84 | ||||
| HCT15 | 2.59 | ||||
| Aspaoligonin B | A549 | 2.55 | |||
| SK-OV-3 | 2.73 | ||||
| SK-MEL-2 | 2.59 | ||||
| XF498 | 2.51 | ||||
| HCT15 | 2.57 | ||||
| Control: adriamycin | |||||
| A549 | 0.004 | ||||
| SK-OV-3 | 0.18 | ||||
| SK-MEL-2 | 0.03 | ||||
| XF498 | 0.012 | ||||
| HCT15 | 0.08 | ||||
|
|
| MTT; cytotoxic | Gnoula et al. ( | ||
| A mixture of balanitin-6 and balanitin-7 | A549 | 0.3 | |||
| U373 | 0.5 | ||||
| PC-3 | 0.9 | ||||
| Bx-PC3 | 1.2 | ||||
| LoVo | 1.5 | ||||
| MCF-7 | 2.6 | ||||
| Control: oxaliplatin | |||||
| A549 | 3.9 | ||||
| U373 | 3.3 | ||||
| PC-3 | 9.2 | ||||
| Bx-PC3 | >10.0 | ||||
| LoVo | 4.7 | ||||
| MCF-7 | 8.9 | ||||
| Control: etoposide | |||||
| A549 | 3.1 | ||||
| U373 | 1.4 | ||||
| PC-3 | >10.0 | ||||
| Bx-PC3 | >10.0 | ||||
| LoVo | 4.9 | ||||
| MCF-7 | >10.0 | ||||
| Control: 7-ethyl-10-hydroxycamptothecin | |||||
| A549 | 0.04 | ||||
| U373 | 0.001 | ||||
| PC-3 | 0.2 | ||||
| Bx-PC3 | 0.07 | ||||
| LoVo | 0.4 | ||||
| MCF-7 | 0.03 | ||||
| Control: Taxol® | |||||
| A549 | 0.009 | ||||
| U373 | 0.001 | ||||
| PC-3 | 0.002 | ||||
| Bx-PC3 | 0.003 | ||||
| LoVo | 0.005 | ||||
| MCF-7 | 0.001 | ||||
|
| Borivilianoside H |
| MTT; cytotoxic | Acharya et al. ( | |
| HT-29 | 2.6 | ||||
| HCT 116 | 0.38 | ||||
| Control: paclitaxel | |||||
| HT-29 | 3.6 × 10−3 | ||||
| HCT 116 | 1.1 × 10−3 | ||||
|
| Pennogenin-3- | Bel-7402 | 10 μmol l−1 (99.1% inhib.) | MTT; antiproliferative | Liu et al. ( |
| SMMC7721 |
| ||||
| Pennogenin-3- | Bel-7402 | 10 μmol l−1 (92.6% inhib.) | |||
| SMMC7721 |
| ||||
|
|
| MTT; antiproliferative | Hu et al. ( | ||
| (25 | HepG2 | 9.02 | |||
| HEK293 | 13.21 | ||||
| MCF7 | 16.74 | ||||
|
|
| MTT; cytotoxic | Siu et al. ( | ||
| Polyphyllin D | NCI-H460 | 3.0 | |||
| SF-268 | 3.0 | ||||
| Hep G2 | 3.5 | ||||
| HeLa | 3.7 | ||||
| MCF-7 | 3.7 | ||||
| HEK-293 | 11.0 | ||||
| Control: cisplatin | |||||
| NCI-H460 | 25 | ||||
| SF-268 | 15.6 | ||||
| Hep G2 | 20.2 | ||||
| HeLa | 11.6 | ||||
| MCF-7 | 19 | ||||
| HEK-293 | >100 | ||||
|
| 2.5 μg ml−1 | MTT; cytotoxic | Yun et al. ( | ||
| Diosgenin-3- | HepG2 | 60.59% dead cells | |||
| SGC7901 | 70.14% dead cells | ||||
| BxPC3 | 76.52% dead cells | ||||
| Pennogenin-3- | HepG2 | 44.22% dead cells | |||
| SGC7901 | 50.13% dead cells | ||||
| BxPC3 | 73.32% dead cells | ||||
| Diosgenin-3- | HepG2 | 83.76% dead cells | |||
| SGC7901 | 88.19% dead cells | ||||
| BxPC3 | 87.06% dead cells | ||||
| Pennogenin-3- | HepG2 | 65.22% dead cells | |||
| SGC7901 | 70.39% dead cells | ||||
| BxPC3 | 79.64% dead cells | ||||
| Diosgenin-3- | HepG2 | 68.35% dead cells | |||
| SGC7901 | 77.34% dead cells | ||||
| BxPC3 | 76.63% dead cells | ||||
| Diosgenin-3- | HepG2 | 61.70% dead cells | |||
| SGC7901 | 75.81% dead cells | ||||
| BxPC3 | 82.92% dead cells | ||||
| Pennogenin-3- | HepG2 | 35.75% dead cells | |||
| SGC7901 | 47.58% dead cells | ||||
| BxPC3 | 81.77% dead cells | ||||
| Control: epirubicin-HCl | |||||
| HepG2 | 78.89% dead cells | ||||
| SGC7901 | 70.73% dead cells | ||||
| BxPC3 | 65.78% dead cells | ||||
|
|
| MTT; cytotoxic | Yan et al. ( | ||
| Diosgenin-3- | LA795 | 1.85 | |||
| Pennogenin-3- | 5.14 | ||||
| Diosgenin-3- | 3.06 | ||||
| Pennogenin-3- | 2.26 | ||||
| Diosgenin-3- | 1.35 | ||||
|
|
| MTT; cytotoxic | Zhao et al. ( | ||
| Pennogenin-3- | HL-60 | 0.51 | |||
| Tg | 0.30 | ||||
| Tb | 1.72 | ||||
| Pennogenin-3- | 3.75 | ||||
| Pa | 0.18 | ||||
| Pb | 0.14 | ||||
| Gracillin | 0.53 | ||||
| Prosapogenin A of dioscin | 0.38 | ||||
| Reclinatoside | 0.52 | ||||
| Loureiroside | 0.72 | ||||
| Control: cis-diamminedichloro-platinum | |||||
| 0.038 | |||||
|
|
| MTT; cytotoxic | Yang and Yang ( | ||
| Polypunctoside A | HeLa | 39.8 | |||
| Polypunctoside B | 3.2 | ||||
| Polypunctoside C | 2.5 | ||||
| Polypunctoside D | 2.6 | ||||
| Dioscin | 20.4 | ||||
| Control: cisplatin | |||||
| 0.75 | |||||
|
|
| SRB; antiproliferative | Pettit et al. ( | ||
| Sansevistatin 1 | P388 | 1.6 | |||
| BXPC-3 | 1.1 | ||||
| MCF-7 | 1.1 | ||||
| SF-268 | 1.3 | ||||
| NCI-H460 | 0.43 | ||||
| KM20L2 | 0.47 | ||||
| DU-145 | 1.0 | ||||
| Sansevistatin 2 | P388 | 1.7 | |||
| BXPC-3 | 0.93 | ||||
| MCF-7 | 0.62 | ||||
| SF-268 | 0.68 | ||||
| NCI-H460 | 0.26 | ||||
| KM20L2 | 0.22 | ||||
| DU-145 | 0.42 | ||||
| Dioscin | P388 | 1.5 | |||
| BXPC-3 | 1.1 | ||||
| MCF-7 | 1.6 | ||||
| SF-268 | 1.2 | ||||
| NCI-H460 | 1.6 | ||||
| KM20L2 | 1.6 | ||||
| DU-145 | 1.6 | ||||
| 3β- | P388 | 1.5 | |||
| BXPC-3 | 1.8 | ||||
| MCF-7 | 2 | ||||
| SF-268 | 1.8 | ||||
| NCI-H460 | 1.8 | ||||
| KM20L2 | 1.7 | ||||
| DU-145 | 1.6 | ||||
| 3β- | P388 | 2.6 | |||
| BXPC-3 | 1.7 | ||||
| MCF-7 | 1.4 | ||||
| SF-268 | 1.3 | ||||
| NCI-H460 | 1.2 | ||||
| KM20L2 | 0.5 | ||||
| DU-145 | 1.1 | ||||
|
|
| MTT; cytotoxic | Zhou et al. ( | ||
| Degalactotigonin | HepG2 | 0.25 | |||
| NCI-H460 | 4.49 | ||||
| MCF-7 | 1.57 | ||||
| SF-268 | 3.19 | ||||
| Control: 10-hydroxycamptothecine | |||||
| HepG2 | 6.49 | ||||
| NCI-H460 | 38.55 | ||||
| MCF-7 | 19.12 | ||||
| SF-268 | 29.88 | ||||
|
|
| MTT; cytotoxic | Lu et al. ( | ||
| Yamogenin-3- | MGC-803 | 25.2 | |||
| HepG2 | 32.7 | ||||
| AS49 | 34.2 | ||||
| MCF-7 | 29.4 | ||||
| Neochlorogenin-3- | MGC-803 | 57.5 | |||
| HepG2 | 65.5 | ||||
| AS49 | 58.3 | ||||
| MCF-7 | 48.4 | ||||
| Control: cis-diammine-dichloroplatinum | |||||
| MGC-803 | 14.4 | ||||
| HepG2 | 13.2 | ||||
| AS49 | 14.1 | ||||
| MCF-7 | 15.3 | ||||
|
|
| Acid phosphatase assay; | Perrone et al. ( | ||
| (25 | U937 | 0.5 | |||
| Gitonin | U937 | 0.1 | WST1; cytotoxic | ||
| MCF-7 | 3.0 | ||||
| HepG2 | 3.0 | ||||
| Control: resveratrol | |||||
| U937 | 17.0 | ||||
| MCF-7 | 100 | ||||
| HepG2 | 50 | ||||
|
| 10 μg ml−1 | MTT; antiproliferative | Zou et al. ( | ||
| Fraction containing: | HeLa | (81% inhib.) | |||
(25 and (25 | HL-60 | (92% inhib.) | |||
|
|
| MTT; cytotoxic | Xie et al. ( | ||
| Ypsilandroside G | K562 | 4.4 | |||
| Pennogenin-3- | SPC-A-1 | 6.3 | |||
| BGC-823 | 6.9 | ||||
| Eca-109 | 8.0 | ||||
| AGS | 8.9 | ||||
| K562 | 4.7 | ||||
| SPC-A-1 | 6.3 | ||||
| BGC-823 | 6.9 | ||||
| Eca-109 | 8.0 | ||||
| AGS | 8.9 | ||||
| Control: cisplatin—data not given |
Cancer cell lines: Prostate: LNCaP, PC-3, DU-145; Leukemia: CEM, K562, HL60, *L1210, P388; Ovarian: SK-OV-3, A2780, OVCAR3, HO-8910; Breast: MDA-MB-231, MCF-7, MDA-MB-453, MDA-MB-435; Lung: A-549, H522-T1, COR-L23, NCI-H460, LTEP-a-2, *LA795, SPC-A-1; Melanoma: G361, MEL-5, A375, C32, *B16F1, *B16F10, SK-MEL-2, HTB-140; Colon: HCT-15, HT-29, WiDr, HCT116, CaCo-2, SW1116, HCT-8, DLD-1, LoVo, KM20L2; Lymphoma: U937; Pharynx: CNE, KB, Eca-109; Liver: HepG2, Huh-7D12, Bel-7402, Hepa59T/VGH, SMMC7721; Stomach: MGC-803, MKN-45, BGC-803, BGC823, KATO-III, SGC7901, AGS; Pancreas: Bx-PC3; CNS: U251, SF268, *C6, U251MG, U373, Daoy, XF498; Renal: ACHN; Bone: 1547, *WEHI-164, *XC, RPMI 8226; Uterus: HeLa
Normal cell lines: Fibroblasts: HSF, BJ-H-tert, 142BR, HFL-I, WS1; Macrophages: *RAW 264.7, *J774.A1; Epithelium/endothelium: EVC-304, MCF-10A; Kidney embryonic: HEK-293; * Murine origin
Concentration: IC50 half maximal inhibitory concentration; ED50 effective dose; GI50 growth inhibition; LC50 lethal concentration; LD50 lethal dose
Assays: MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; XTT—2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide; MTS—3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; WST-1—2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium, SRB—sulphorhodamine. PI—propidium iodide. NRR—neutral red release
Fig. 1Chemical structures of polyphyllin D (1), methyl protodioscin (2), albizoside C (3) and saponin PE (4)
Structure-cytotoxic activity relationships of saponins
| Structural feature | Enhancement of activity | References |
|---|---|---|
| Type of triterpene aglycone | Oleanane > lupane | Bang et al. ( |
| Oleanane > hopane | Hamed et al. ( | |
| Lupane > germanicane | Thibeault et al. ( | |
| Oleanolic acid > hederagenin in vitro | Gauthier et al. ( | |
| Hederagenin > oleanolic acid in vivo | Bang et al. ( | |
| Betulinic acid > betulin | Thibeault et al. ( | |
| Oleanane-type aglycone | Free carboxyl at C-28 | Chwalek et al. ( |
| Acylation at C-21 and C-22 | Zhang and Li ( | |
| Oleanane-type aglycone acylated at C-21 and C-22 | Methyl at C-24 > hydroxymethyl at C-24 | Chan et al. ( |
| Free hydroxyl at C-16 | Yu et al. ( | |
| 13,28-epoxyoleanane-type aglycone | Aldehyde/methyl at C-30 > carboxyl/hydroxymethyl at C-30 | Tian et al. ( |
| Free hydroxyl at C-16 | Chang et al. ( | |
| Acacic acid-type aglycone | Oligosaccharide ester at C-28 | Cao et al. ( |
| Free hydroxyl at C-16 | Cao et al. ( | |
| Acylation at C-21 (monoterpene-quinovopyranosyl moiety) | Cao et al. ( | |
Oleanane-type saponins Ursane-type saponins Lupane-type saponins | Monodesmosides > bidesmosides | Calabria et al. ( |
| Acacic acid-type saponins | Bidesmosides > monodesmosides | Zou et al. ( |
| Oleanane-type saponins | α- | Jung et al. ( |
| α- | Chwalek et al. ( | |
| Branched trisaccharide at C-3 > disaccharide at C-3 | Bang et al. ( | |
| Straight chain length → contradictory data | Jung et al. ( | |
| Lupane-type saponins | α- | Gauthier et al. ( |
| Betulin saponins | α- | Thibeault et al. ( |
| Monomannosides > bimannosides | Cmoch et al. ( | |
| Diosgenyl saponins | α- | Mimaki et al. ( |
| Elongation of sugar chain | Yan et al. ( | |
| Diosgenin and pennogenin saponins | Terminal Rha | Zhao et al. ( |
Mechanisms of cytotoxic activity of saponins
| Process | Mode of action | References |
|---|---|---|
| Apoptosis intrinsic pathway | Cytochrome c release | Sun et al. ( |
| Mitochondria membrane depolimerization | ||
| GADD153/CHOP transcription factor expression increase | ||
| Caspase 3 and 9 activation | ||
| PARP-1 cleavage | ||
| MAPK cascade activation | ||
| p-STAT-3 decrease | ||
| Bcl-2, c-myc, survivin downregulation | ||
| VEGF downregulation | ||
| p53 stimulation | ||
| NF-κB inhibition | ||
| JAKs dephosphorylation | ||
| Protein phosphatase-1 activation | ||
| Intracellular Ca2+ homeostasis disruption | ||
| Apoptosis extrinsic pathway | Fas enhancement | Hsu et al. ( |
| Fas ligand enhancement | ||
| Apoptosis non-specified | Telomerase activity inhibition | Kim et al. ( |
| Cell cycle arrest | CDK6 downregulation | Sun et al. ( |
| Cyclin D3 downregulation | ||
| Cyclin D1 downregulation | ||
| p27kip upregulation | ||
| CDK2 inhibition | ||
| Autophagy | Microtubule-associated protein light chain-3 increase | Ellington et al. ( |
| Autophagic vacuoles number increase | ||
| AMPK-TSC2 regulation | ||
| Cellular ATP decrease | ||
| AMPK activation | ||
| Angiogenesis inhibition | Thrombospondin-1 expression increase | Wang et al. ( |
| PKC expression decrease | ||
| ERK activation | ||
| P38MAPK activation | ||
| Endothelial cell proliferation inhibition | ||
| Tube-formation inhibition | ||
| Cytoskeleton disintegration | Microtubule dissasembly | Li et al. ( |
| Tubulin polymerization inhibition | ||
| Actin filaments disruption | ||
| Intracellular ATP decrease | ||
| Nucleus morphology changes | ||
| Metastasis inhibition | Cell motility and migration inhibition | Tian et al. ( |
| Cell adhesion inhibition | ||
| MMP-2, MMP-9 downregulation | ||
| TIMP-2 upregulation |